Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

CytomX Therapeutics Inc CTMX

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.


NDAQ:CTMX - Post by User

Post by AviseAnalyticson Jan 26, 2022 8:10am
132 Views
Post# 34361349

EMERGING PARADIGMS IN TREATMENT OF MELANOMA!

EMERGING PARADIGMS IN TREATMENT OF MELANOMA!$CTMX $NKTR $MGNX $IDYA $ALKS

Melanoma, a form of skin cancer, accounts for about 1% of skin cancers but is responsible for over 7,650 deaths every year as per an estimate by the American Cancer Society, these numbers are steadily rising over the years with approximately 99,780 new melanomas diagnosis being made each year. 

However, the prohibitive cost of treatment may prove challenging and affect the growth prospects to an extent. A number of clinical trials are underway in the melanoma treatment industry with companies introducing unique first-in-class treatment options, some of which are enumerated in our today's coverage. 

Read on to know more!

https://www.aviseanalytics.com/emerging-paradigms-in-treatment-of-melanoma/ 
 
Bullboard Posts
Next >>